Coronavirus News LIVE Updates: India reports 18,177 cases, 217 deaths in past 24 hours; recovery rate now 96.15%

-

09:52 (IST)

Coronavirus News LATEST Updates

India reports over 18,000 new cases; tally now at 1.03 cr

India recorded 18,177 new COVID-19 cases in a day, while 99,27,310 people have recuperated so far pushing the national recovery rate to 96.15 percent on Sunday, according to the Union Health Ministry data.

The total coronavirus cases mounted to 1,03,23,965 and the death toll climbed to 1,49,435 with the novel coronavirus virus claiming 217 lives in a span of 24 hours in the country, the data updated at 8 am showed. The COVID-19 case fatality rate stood at 1.45 percent.

There are 2,47,220 active cases of coronavirus infection in the country which comprises 2.39 percent of the total caseload, the data stated.

According to the ICMR, a cumulative total of 17,48,99,783 samples have been tested up to 2 January with 9,58,125 samples being tested on Saturday.

09:48 (IST)

Coronavirus News LATEST Updates

DCGI to brief media at 11 am today

The Drugs Controller General of India (DCGI) will brief the media at 11.00 am today on the COVID-19 vaccine. At least two vaccine candidates are awaiting final emergency use authorisation from the DCGi.

09:46 (IST)

Coronavirus News LATEST Updates

85 people test positive in Chennai's ITC Grand Chola hotel 

About 85 people, including staff members of ITC Grand Chola in Chennai's Guindy area, have tested positive for COVID-19 since 15 December last year, a senior official said on Saturday. Of the total of 609 samples collected till date, 85 were found to be positive.

Following this, the Greater Chennai Corporation has been instructed to carry out saturation testing of all the guests at the hotel, Health Secretary J Radhakrishnan said.

ITC Grand Chola, in a release, said all events at the property have been conducted in adherence to the norms mandated by the authorities.

Additionally, only 50 percent capacity of the hall is used to ensure maximum distancing and safety, it said.

Read full report here

09:44 (IST)

Coronavirus News LATEST Updates

India first country to successfully culture UK virus variant, says ICMR

The Indian Council of Medical Research on Saturday said that it has successfully isolated and cultured the new variant of the coronavirus identified in the United Kingdom. The top medical body claimed that no other country has so far reported success in this area.

Culture is the process by which cells are grown under controlled conditions, generally outside their natural environment.

Coronavirus News LATEST Updates: India recorded 18,177 new COVID-19 cases in a day, while 99,27,310 people have recuperated so far pushing the national recovery rate to 96.15 percent on Sunday, according to the Union Health Ministry data.

The total coronavirus cases mounted to 1,03,23,965 and the toll climbed to 1,49,435 with the novel coronavirus virus claiming 217 lives in a span of 24 hours in the country, the data updated at 8 am showed. The COVID-19 case fatality rate stood at 1.45 percent

An expert panel of India's central drug authority on Saturday recommended granting permission for restricted use of Bharat Biotech-developed indigenous COVID-19 vaccine Covaxin in emergency situation, especially in the context of infection by mutant strains, officials said.

The recommendation for Bharat Biotech's vaccine came a day after the panel cleared the Serum Institute of India's emergency use athorisation application for the Oxford-AstraZeneca vaccine Covishield.

This paves the way for the roll-out of at least two vaccines in India in the coming days, while two more are in advance stages of development.

At a press conference in New Delhi, Union minister Prakash Javadekar said India was probably the only country where four vaccines were in the pipeline.

Asked about some religious figures raising doubts over vaccines, Javadekar said "our vaccine is effective" and the rest of the world was also using it. He added that vaccines are introduced after tests and those that would be brought in would be safe.

Union Health Minister Harsh Vardhan appealed to people on Saturday not to be misguided by "rumours" regarding the safety and efficacy of the coronavirus vaccine, and said, "We will not compromise on any protocol before approving a vaccine."

The Union Health Ministry on Saturday said the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission to the Serum Institute of Institute (SII) for restricted emergency use of Covishield in India, subject to multiple regulatory conditionalities.

"The SEC of CDSCO met on January 1 and 2 and made the recommendations for the consideration and final decision of the Drugs Controller General of India (DCGI)," the ministry said.

Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

The SEC again deliberated on the emergency use authorisation (EUA) application of Bharat Biotech on Saturday after it presented the updated data, justification and requested for consideration of their proposal in the wake of incidence of new mutated coronavirus infection.

It recommended "grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, specially in the context of infection by mutant strains, to Bharat Biotech," the health ministry stated.

According to sources, the committee, however, stated that the firm shall continue the ongoing phase 3 clinical trial and submit data emerging from the trial as and when available.

The committee noted that the vaccine is an inactivated whole virion, coronavirus vaccine, having potential to target mutated coronavirus strains, a source said. The data generated so far demonstrates a strong immune response (both antibody as well as T cell) and in-vitro viral neutralisation.

While granting the restricted emergency use approval for the Oxford COVID-19 vaccine on Friday, the panel had imposed certain regulatory provisions, including that the shot is indicated for active immunisation in individuals of 18 years or more to prevent the disease and that SII should submit safety, efficacy and immunogenicity data from the ongoing clinical trials in the country and across the globe for review at the earliest.

Also, the Pune-based firm should submit the safety data including the data on adverse events following immunisation (AEFI) and adverse event of special interest (AESI) with due analysis every 15 days for the first two months and monthly thereafter till the completion of the ongoing clinical trial in the country, according to the recommendations.

Thereafter, the firm should submit the safety data as per the provisions and standard procedures.

According to sources, the recommendations stated that the vaccine should be supplied along with fact-sheet and separate leaflet for the guidance of the healthcare provider.

The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.

According to sources, the firm had presented the details of the conditions and restrictions under which AstraZeneca was granted emergency use authorisation in the UK and the revised fact sheet and prescribing information in Indian context as required by the committee.

SII had applied to the Drugs Controller General of India (DCGI) for EUA for Oxford COVID-19 vaccine on December 6, while the Hyderabad-based Bharat Biotech had sought the nod for its indigenously developed Covaxin on December 7.

Pfizer had applied for regulatory approval for its vaccine on December 4 has not yet turned for deliberation.

After detailed deliberations, the SEC has also recommended for grant of permission to Cadila Healthcare Ltd in Ahmedabad for conduct of phase-3 clinical trial protocol for its vaccine candidate.



from Firstpost India Latest News https://ift.tt/3aZPAN2
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more